Bio latch, a San Francisco, California-based company that is building a data infrastructure for bioinformatics, closed a $ 5 million funding round.
The cycle was led by Lux Capital with participation from General Catalyst, Haystack, Fifty Years, and Asimov co-founder and CEO, Alec Nielsen, Ph.D.
Founded in 2021 by Alfredo Andere, Kyle Giffin and Kenny Workman who met as undergraduates at the University of California at Berkeley, Latch Bio is building a web platform that allows any biologist to analyze CRISPR data without any code or cloud infrastructure configuration.
Thanks to the platform, any researcher can now create a centralized one-stop-shop to store, transform and visualize their data without writing any code. Using plugins, users can import files from their existing data stack, including Amazon S3, Benchling, and BaseSpace from Illumina. Biologists have access to dozens of workflows, including CRISPResso, MAGECK, CasTLE, Cas.py, MultiQC, and CasOffinder, among others. After performing a specific workflow, users can further query the results using the built-in genomic viewer and quality checks. The platform is offered free of charge to users of university research.